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The lysosomal storage disorder galactosialidosis results from a primary deficiency of the protective 
protein/cathepsin A (PPCA), which in turn affects the activities of p-galactosidase and neuraminidase. Mice 
homozygous for a null mutation at the PPCA locus present with signs of the disease shortly after birth and 
develop a phenotype closely resembling human patients with galactosialidosis. Most of their tissues show 
characteristic vacuolation of specific cells, attributable to lysosomal storage. Excessive excretion of 
sialyloligosaccharides in urine is diagnostic of the disease. Affected mice progressively deteriorate as a 
consequence of severe organ dysfunction, especially of the kidney. The deficient phenotype can be corrected 
by transplanting null mutants with bone marrow from a transgenic line overexpressing human PPCA in 
erythroid precursor cells. The transgenic bone marrow gives a more efficient and complete correction of the 
visceral organs than normal bone marrow. Our data demonstrate the usefulness of this animal model, very 
similar to the human disease, for experimenting therapeutic strategies aimed to deliver the functional protein 
or gene to affected organs. Furthermore, they suggest the feasibility of gene therapy for galactosialidosis and 
other disorders, using bone marrow cells engineered to overexpress and secrete the correcting lysosomal 
protein. 
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Galactosialidosis (for review, see d'Azzo et al. 1995) is a 
lysosomal storage disease, inherited as an autosomal re­
cessive trait and characterized by a combined deficiency 
of p-D-galactosidase and N-acetyl-a-neuraminidase, sec­
ondary to a defect of the protective protein/cathepsin A 
(PPCA) (Wenger et al. 1978; d'Azzo et al. 1982). This 
serine carboxypeptidase (Galjart et al. 1988; Rawlings 
and Barrett 1994) has at least two distinct functions. 
First, as demonstrated by copurification experiments 
(Verheijen et al. 1982; Yamamoto and Nishimura 1987; 
Potier et al. 1990; Scheibe et al. 1990; Hubbes et al. 
1992), it associates with the two glycosidases, thereby 
modulating their intralysosomal stability and activity 
(Hoogeveen et al. 1983; van der Horst et al. 1989; Galjart 
et al. 1991). Second, the protein is catalytically active as 
a lysosomal cathepsin at acidic pH, as well as a deami-
^Cotresponding authot. 
dase/esterase at neutral pH, and has been shown to par­
ticipate in the inactivation of selected neuropeptides like 
substance P, oxytocin, and endothelin I (Jackman et al. 
1990; Galjart et al. 1991; Jackman et al. 1992; Hanna et 
al. 1994). Mammalian and avian protective proteins are 
highly conserved and share homology to yeast and plant 
serine carboxypeptidases (Galjart et al. 1988; Galjart et 
al. 1991). The murine and avian enzymes can even sub­
stitute for their human homolog to stabilize and activate 
human p-galactosidase and neuraminidase (Galjart et al. 
1991). 
Patients with galactosialidosis have clinical manifes­
tations indicative of a lysosomal disorder, including 
coarse facies, ocular cherry red spots, vertebral changes, 
foamy cells in the bone marrow, and vacuolated lympho­
cytes in peripheral blood. Based on the age of onset of the 
symptoms, three clinical phenotypes are distinguished: 
early infantile, late infantile, and juvenile/adult vari­
ants. The most severe early infantile form is associated 
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with fetal hydrops, diffuse edema, ascites, hepatospleno-
megaly, psychomotor delay, bone deformity, and severe 
heart and kidney involvement. Death occurs within the 
first year of age, likely as a result of renal failure. Late 
infantile and juvenile/adult patients have a later onset 
and slower progression of the disease; however, whereas 
adult patients have central nervous system (CNS) in­
volvement, the late infantile types are not mentally re­
tarded or only mildly so. In spite of the triple enzyme 
deficiency, the storage products isolated from tissues and 
urine of galactosialidosis patients are primarily sialy-
lated oligosaccharides (Okada et al. 1978; van Pelt et al. 
1988a,b, 1989). The characteristic pathology of the dis­
ease includes vacuolation of cells in the central, periph­
eral, and autonomic nervous systems, retina, liver, kid­
ney, skin, and peripheral blood (d'Azzo et al. 1995). 
There is currently no effective therapy for galactosial­
idosis or for other lysosomal disorders with CNS in­
volvement. Transplantation of allogeneic bone marrow 
as a source of normal enzyme has proven of limited ben­
efit in human studies with other lysosomal diseases (for 
review, see Krivit et al. 1992; Hoogerbrugge et al. 1995), 
but has never been tried for galactosialidosis. Also in 
naturally occurring animal models with these disorders, 
the effect of bone marrow transplantation (BMT) has 
been variable (for review, see Haskins et al. 1991). Im­
provement of the pathology was observed after BMT in 
cats with a-mannosidosis (Walkley et al. 1994a), but 
only partial correction was obtained with this procedure 
in mice with mucopolysaccharidosis VII (Birkenmeier et 
al. 1991) and no amelioration was detected in treated 
Gjvi2-gangliosidosis cats (Walkley et al. 1994b). This dif­
ference may depend on the number of perivascular 
monocytes/macrophages originating from the graft but 
also on differential secretion of the correcting enzyme by 
donor-derived cells, as seems to be the case for a-man-
nosidase and ^-hexosaminidase, at least in in vitro stud­
ies (Dobrenis et al. 1994). Other novel approaches, like 
intraperitoneal implant of fibroblasts organoids (Moul-
lier et al. 1995) or direct transfer of neuronal progenitor 
cells (Snyder et al. 1995), have been employed recently 
for the local delivery of exogenous functional enzyme to 
the liver and the CNS, respectively. Overall, these stud­
ies establish the validity of suitable animal models, 
which closely resemble the human disease, to evaluate 
therapeutic strategies for the correction of disorders like 
galactosialidosis. Although sheep with a combined p-ga-
lactosidase and neuraminidase deficiency have been 
identified (Ahern-Rindell et al. 1988), both the localiza­
tion of severe storage only to neurons and the enzymatic 
characteristics differentiate this model from the human 
disease. Recently, a disease with pathology similar to the 
adult form of galactosialidosis was described in a Schip-
perke dog (Knowles et al. 1993), but the biochemical data 
were insufficient to verify the diagnosis. To produce an 
animal model for galactosialidosis we have generated 
mice carrying a null mutation at the PPCA locus. Defi­
cient animals are viable and fertile but exhibit severe 
abnormalities soon after birth that closely resemble 
those found in galactosialidosis patients. They also de­
velop the characteristic histopathology of the human 
disease. Thus, this mouse model provides an attractive 
opportunity to study the pathogenesis and pathophysiol­
ogy of the disease and to evaluate experimental thera­
pies, including gene therapy. In this report we have 
tested the hypothesis that substantial secretion of PPCA 
by genetically modified bone marrow cells could trans­
late into a more timely and effective correction of the 
lesions in affected mice. We demonstrate that treatment 
of the ( - / - ) phenotype with transgenic bone marrow 
overexpressing the human PPCA in erythroid precursors, 
which also secrete the protein at high levels, can im­
prove the pathological conditions better than normal 
bone marrow cells. These results give the first indication 
of the potential of overproducing and secreting he­
matopoietic cells for the treatment of galactosialidosis 
and possibly other similar disorders. 
Results 
Generation of PPCA-deficient mice 
A targeting vector for homologous recombination at the 
murine PPCA locus was constructed as outlined in Fig­
ure lA. The position of the positive selectable marker 
prevents translation of the polypeptide and thus the tar­
geted replacement constitutes a genuine null mutation. 
Targeted E14 embryonic stem (ES) cells were obtained at 
a frequency of 13%-15%. Chimeric males derived from 
two independent clones (28 and 139) yielded germ-line 
transmission of the null allele. Interbreeding of heterozy-
gotes (+ / - ) from both clones readily generated homozy­
gous ( - / - ) mice. Offspring were genotyped by Southern 
blotting and hybridization with a 5' external probe (Fig. 
IB). Combined data from crosses between clone 28 and/ 
or clone 139 heterozygotes showed a distribution of 24% 
[ + / + ], 20% ( - / - ) , and 56% (+ / - ) in 292 offspring 
analyzed, suggesting that an intact PPCA gene is not 
required for normal embryonic development of homozy­
gous null mice. Northern blot analysis (Fig. IC) of total 
RNA isolated from PPCA (— / - ) tissues confirmed the 
lack of a PPCA transcript in deficient mice. 
Biochemical analysis of PPCA-deficient mice 
The engineered mutation rendered (— / —) mice unable 
to encode the PPCA protein, as established by assaying 
cathepsin A activity in cultured fibroblasts and tissues 
from { + / + ), (-I- / - ) , and ( - / - ) mutant animals of dif­
ferent age (Table 1). This catalytic activity either was 
absent or reduced severely in tissues of homozygous mu­
tant mice, with the levels ranging from nondetectable in 
bone marrow to —8% of normal in liver. The small, re­
sidual activity measured in some of the samples may be 
attributable to the presence of catalytically related pro­
teins that have a low affinity for the Z-Phe-Ala substrate. 
Heterozygous mice showed clear intermediate values 
(Table 1). Because direct biochemical evidence of galac­
tosialidosis in human patients is the combined defi­
ciency of neuraminidase and (i-galactosidase in fibro-
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Figure 1. Targeted disruption of the PPCA locus by homolo­
gous recombination. [A] Structure of a portion of the PPCA 
gene, the targeting construct, and the predicted structure of the 
targeted PPCA locus following homologous recombination. 
Only the relevant restriction sites are shown: (E) £coRI; (N) 
Ndel. The numbered solid boxes represent exons. The labeled 
boxes indicate the position of the respective 5' and 3' hy probes. 
Horizontal single arrows indicate the direction of transcription 
of the hygio and TK cassettes. Two-headed arrows show the 
position and size of Ndel restriction fragments diagnostic for 
proper targeting of the locus. [B] Southern blot analysis of Ndel-
digested genomic DNA of nine mice from one litter resulting 
from a cross between two PPCA ( + / - ) mice. The blot was 
hybridized with the 5' Ndel-EcoRl probe. The wild-type and 
mutant alleles are indicated by 12- and 5-kb Ndel fragments, 
respectively. (C). Northern blot analysis of PPCA mRNA from 
mouse tissues. Total RNAs: (20 jjLg) from brain (B), kidney (K), 
and liver (L) of a wild-type (-I- / -t-) mouse and two mutant ( - / 
- ) mice derived from ES clone 28 and 139 were analyzed by 
Northern blotting with the PPCA mouse cDNA probe. The 
expected 2-kb mRNA, detected in normal tissues, is absent in 
tissues from the mutant mice. 
blasts and leukocytes (d'Azzo et al. 1995), ŵ e assessed 
these parameters in the mutant mice. The deficiency of 
cathepsin A in ( - / - ) tissues directly influenced the ac­
tivity of neuraminidase^ which was severely reduced, es­
pecially in fibroblasts and kidney samples (Table 1). 
However, p-galactosidase levels varied considerably for 
the different tissues from deficient mice, being - 2 0 % of 
normal levels in fibroblasts, as found in human galacto­
sialidosis (10%-15%), but even higher than normal in 
liver. These results suggest that murine |3-galactosidase 
may be less dependent for its stability and activity on 
complex formation with PPCA than is murine neur­
aminidase. 
A second parameter used in clinical diagnosis is the 
overexcretion of undegraded sialyloligosaccharides in 
the urine of affected individuals (van Pelt et al. 1989). 
The total content of these metabolites in PPCA ( - / - ) 
mice thus was determined for urine from PPCA ( - / - ) , 
(-I- / - ) , and (-I- / 4-) mice. Twenty-one affected mice, 
tested between the age of 2 and 5 months excreted 3-10 
times more sialylated oligosaccharides in urine than 
their normal and heterozygous littermates (Table 2). The 
amount of accumulated products increased progressively 
with time, eventually reaching levels 25 times higher 
than controls and heterozygotes in seven ( - / - ) mice 
tested at the age of 6-8 months. These biochemical data 
clearly mirror the situation for humans with galactosial­
idosis and establish the validity of this model as an ex­
perimental substrate. 
Phenotypic characterization and histopathology 
of deficient mice 
PPCA ( - / - ) mice are viable and fertile, and die at —12 
months of age. At birth and during the first 6 weeks of 
life their gross appearance was normal, except for an ap-
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+ / + 
159 ± 9 
135 ± 14 
20 ± 3 
114 ± 16 
77 ± 19 
163 ± 27 
+ / -
98 ± 17 
61 ± 8 
10 ± 2 
43 ± 18 
31 ± 13 
N.D. 
- / -
1.3 ± 0.9 
1.8 ± 0.9 
0.7 ± 0.3 
5.5 ± 2.3 
3.8 ± 1.1 
0.0 ± 0.0 
+ / + 
23.00 ± 0.10 
40.00 ± 6.40 
3.06 ± 0.36 
4.00 ± 1.92 
3.78 ± 0.66 
3.66 ± 0.36 
- / -
0.43 ±0.17 
0.57 ± 0.09 
0.98 ± 0.19 
0.94 ± 0.21 
0.42 ± 0.07 
0.19 ± 0.02 
+ / + 
812 ± 82 
275 ± 72 
68 ±21 
291 ±51 
68 ± 8 
119 ± 11 
- / -
263 ± 50 
176 ± 25 
59 ± 9 
240 ±46 
144 ± 22 
106 ± 25 
Fibroblast cell lysates and total tissue homogenates in H2O from PP normal ( + / + ), heterozygous ( + / - ) , and homozygous ( - / - ) mice 
were assayed for cathepsin A activity, using the acylated dipeptide Z-Phe-Ala, and for neuraminidase and p-galactosidase activities, 
using synthetic 4-methylumbelliferyl substrates. Values represent means ± S.E.M. of measurements done on 4 (+ / + ), 2 (+ / - ) , and 7 
( - / - ) mice. All mice were between 2 and 8 weeks of age and were derived from ES cell clones 28 and 139. (N.D.) Not done. 
parent flattening of the face. However, the majority of 
young ( - / - 1 mice weighed 25%-40% less than (+ / +) 
and (+ / - ) littermates and were identified readily by 
size. Two of the smallest mice died spontaneously at 3 
weeks of age and were found to have hepatic and splenic 
enlargement. No distinguishable skeletal deformities 
were observed in the young ( - / - ) mice, but their phys­
ical condition overall worsened with age. Progressive 
and diffuse edema was accompanied by apparent ataxic 
movements and tremor. The characteristic broad face, 
rough coat, and extensive swelling of subcutaneous tis­
sues, limbs, and eyelids are obvious in the 10-month-old 
( - / - 1 mouse shown in Figure 2. 
Visceromegaly is a specific clinical abnormality asso­
ciated with the early and sometimes late infantile forms 
with galactosialidosis. This feature was also found in 
PPCA ( - / - ) mice with enlargement of both the liver 
and the spleen being prominent at autopsy (not shown). 
Morphological studies of tissues from ( - / - ) mice were 
carried out on either paraffin, cryosections, or epoxy-
resin sections examined both by light and electron mi­
croscopy. Affected mice were sacrificed at the age of 14 
days, 1 month, 3-4 months, 6 months, and 10 months. 
Signs of metabolic storage were found primarily in the 
reticuloendothelial system of most organs, already no­
ticeable in the first mouse analyzed 14 days after birth. 
Thirty percent of the lymphocytes in peripheral blood 
had translucent vacuoles in their cytoplasm. In the skin, 
foamy macrophages, sometimes clearly perivascular, 
were visible between collagen bundles of the dermis. 
The presence of stored material was confirmed by posi­
tive cytoplasmic staining with periodic acid-Schiff (PAS) 
and diastase treatment (PAS-I-). The kidney appeared to 
be the earliest and most severely affected organ in young 
mutant mice, analogous to the situation for severe hu­
man disease. Electron microscopy of ultrathin sections 
of kidney from a 14-day-old ( - / - ) mouse demonstrated 
vacuolation of the tubular epithelium, most evident in 
the proximal tubules (Fig. 3A), whereas distal tubules 
and glomeruli were less or minimally affected at this 
stage (Fig. 3B). The numerous membrane-bound vacuoles 
representing secondary lysosomes appeared either empty 
or filled with sparse fibrillar structures, reflecting lysos­
omal accumulation of low molecular weight compounds 
(e.g., oligosaccharides or glycopeptides). 
This spectrum of pathological changes worsened pro-
Table 2. Total urinary sialyloligosaccharides in affected and BM-transplanted mice 






























: 155 (range 1663-2310) 
: 117 (range 993-2923) 
: 647 (range 5305-19362) 
: 4845 (range (11200-45763) 
weeks; 3months p.t.) 
weeks; 8 weeks p.t.) 
weeks 3 months p.t.) 
weeks; 9 weeks; 3 months p.t. 
weeks; 9 weeks; 3 months p.t. 
Total sialyloligosaccharides were measured after acid hydroloysis of urine samples with thiobarinturic acid and were expressed in 
nmoles of released neuraminic acids per milligram of creatinine. (BMT-N) PPCA ( - / - ) mice transplanted with bone marrow from a 
normal donor. (BMT-TG) PPCA ( - / - ) mice transplanted with bone marrow from a transgenic mouse, overexpressing human pro­
tective protein in the erythroid lineage. Mice were transplanted at either 2.5 or 5 months of age. Sialyloligosaccharide determinations 
were performed at various time points post-transplantation (p.t.), as specified in parentheses. The values represent the mean of 
independent measurements. 
2626 GENES & DEVELOPMENT 
 Cold Spring Harbor Laboratory Press on February 2, 2021 - Published by genesdev.cshlp.orgDownloaded from 
Figure 2. Gross phenotypic appearance of a PPCA ( - / - ) 
mouse [middle] at 10 months of age, compared to a wild-type 
(+ / + ) littermate [light], and a ( - / - ) littermate [left] trans­
planted 5 months earlier with transgenic BM. The affected 
mouse has a broad face, disheveled coat, and swollen limbs and 
eyelids. In contrast, the BMT mouse clearly has improved in 
appearance. Evidence of edema has disappeared, and the coat is 
shiny and full. 
Mouse model for galactosialidosis and therapy 
ited portions of the brain, there was a significant regional 
variation in the distribution of PAS-positive neurons. 
Entorhinal cortex and hippocampus appeared to be more 
involved (Fig. 4B, d) than the somatosensory cortex (Fig. 
4B, e). In the cerebellum, there was a loss of Purkinje 
cells and some of the remaining Purkinje cells contained 
storage material in their perikarya (not shown). The 
granular cells were well preserved. Extensive storage was 
apparent in the epithelial and stromal cells of the chor­
oid plexi (Fig. 5B, below). Finally, vacuolated cells were 
present in the trigeminal ganglia and the pituitary gland. 
The pituicytes also showed fine vacuolation (Fig. 4C). 
Examination of other organs (i.e., pancreas, small and 
large intestine, lymph nodes, testis, ovaries, uterus, 
heart, bone marrow, and eye) confirmed the presence of 
membrane-bound vacuoles primarily in macrophages 
and cells of epithelial/endothelial origin (not shown). No 
evidence of lysosomal storage was detected in the lungs 
and skeletal muscles. The distribution and type of accu­
mulating cells remained similar in 10-month-old mutant 
mice. 
gressively with age. The toluidine blue- and PAS-stained 
histological sections shown in Figure 4 were derived 
from a ( - / - ) mouse at 6 month of age. In the affected 
kidney the epithelial cells of the proximal tubules were 
filled with swollen lysosomes. The glomeruli also were 
severely impaired by abundant vacuolation of parietal 
and visceral epithelium, endothelium and mesangial 
cells at this stage of the disease. Accumulation of unde-
graded material again was not apparent in the distal tu­
bules. These abnormalities were not observed in control 
specimens, except for small resorption vesicles present 
normally at the apical side of the tubular epithelial cell 
surface (Fig. 4A). No evidence of storage was detected in 
the adrenal glands (not shown). In the ( - / - ) liver, he-
patocytes contained numerous, small membrane-bound 
vacuoles, whereas the Kupffer cells in the sinusoids were 
more affected and acquired the characteristic foamy ap­
pearance (Fig. 4A). Both hepatocytes and Kupffer cells 
stained positive with PAS -I- (not shown). The spleen of 
the diseased mouse showed extensive congestion of the 
sinuses and the marginal zones with foamy macro­
phages, which were also slightly PAS-positive. Further­
more, large cytoplasmic vacuoles were found in the lym­
phoid cells. Megakaryocytes were devoid of storage, de­
spite their extensive lysosomal system (Fig. 4A). 
The histopathology of the brain was examined in par­
affin sections, and portions of the cerebrum and cerebel­
lum were processed for frozen sections stained with PAS 
or for epoxy-resin sections stained with toluidine blue. 
Finely vacuolated storage cells similar to those found in 
the visceral organs also were observed in the brain. They 
often were located around neurons or blood vessels (Fig. 
4B, a-c). Neuronal storage was rather inconspicuous on 
paraffin sections even in older mice. However, on frozen 
sections stained with PAS, affected neurons were iden­
tified easily by a brilliantly red storage material (Fig. 4B, 
d). Although frozen section study was carried out on lim-
Rescue of the galactosialidosis phenotype 
in the mouse model 
The rationale for using allogeneic BMT to treat lysoso­
mal storage disorders is that progenitor bone marrow 
(BM) cells will repopulate the transplanted host and sup­
ply the missing enzyme to deficient cells in the tissues of 
the recipient. Correction takes place when the therapeu­
tic enzyme secreted from normal BM cells is reinternal-
ized by deficient cells, with restoration of lysosomal 
'\tJ> 
B ^ 
Figure 3. Electron microscopy of kidney from a 2-week-old 
( - / - ) mouse. [A] Micro- and macrovacuolation of the proximal 
tubules is apparent. [B] Distal tubules and glomeruli are less, if 
not at all, affected at this stage of the disease. Magnification, 
2000X [A] and 2500x for [B]. 
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Figure 4. Histopathological analysis of a 6-month-old PPCA 
/ - ) mouse compared to a (+ / +) littermate. Semithin tis­
sue sections from kidney (Kid.), liver (Liv.), spleen (SpL), brain 
(Br.), and pituitary (Pit.) were stained with toluidine blue, 
whereas cryosections from the brain were stained with PAS. 
Morphological changes and extensive vacuolation of numer­
ous cell types were detected, reflecting massive lysosomal 
storage. (A) (Original magnifications 400x). In the kidney, ar­
rows 1 and 2 indicate the vacuolation in glomeruli and prox­
imal tubules, respectively; in the liver, 1 and 3 point to bal­
looned Kupffer cells, whereas 2 indicates microvacuolation of 
the hepatocyte. In the spleen, 1 and 2 show a vacuolated mac­
rophage and lymphocyte, respectively, but a megakaryocyte is 
not affected (arrow 3). {B,a] (Magnification, 400x). Some of the 
large neurons in the cerebral cortex have storage vacuoles (ar­
row 2) and endothelial and glial cells show extensive vacuo­
lation (arrows 1 and 3, respectively). {B,b) A greater magnifi­
cation (lOOOx) of a selected area of B,a whereas B,c shows an 
enlarged perivascular cell (lOOOx) with extensive storage vac­
uoles. {B,d] (Magnification, 440x). Neurons in the entorhinal 
cortex contain abundant PAS-I- storage material in their 
perikarya. (B,e] (Magnification, 400x). Only rare neurons con-
:aining PAS -I- storage materials (arrows) are identified in the 
somatosensory cortex. (C) (Magnification, 880x). Pituitary 
l̂and of the ( - / - ) mouse shows vacuolation of pituicytes in 
addition to foamy macrophages. 
function. It is conceivable that higher levels of the cor­
recting protein will relate directly to more timely and 
effective treatment. We have show^n previously that both 
human and murine PPCA precursors, selectively se­
creted by overexpressing cells, undergo endocytosis by 
cultured galactosialidosis fibroblasts via the mannose-6-
phosphate receptor and correct both |3-galactosidase and 
neuraminidase activities (Galjart et al. 1991). Having a 
suitable animal model for galactosialidosis, we now 
could test whether transplantation of affected mice with 
BM cells overexpressing and secreting a functional PPCA 
protein could correct the lysosomal storage better than 
normal bone marrow. Therefore, four transgenic mouse 
lines were generated in which expression of a human 
PPCA transgene was driven by the p-globin promoter 
and locus control region (LCR) of the ^-globin gene 
(Grosveld et al. 1987). The transgenic mice synthesized 
the heterologous human protein at high levels in cells of 
the erythroid lineage. Prior to transplantation, we ascer­
tained that the product of the transgene also was se­
creted by BM cells to the extent that the high uptake 
precursor form of the protein was detectable in plasma 
and would undergo endocytosis by recipient cells. For 
this experiment, total BM cells derived from either trans­
genic or normal mice were cultured in the presence of 
cytokines for 5 days. The conditioned medium from 
these cultures, as well as serum from the same animals, 
was first assayed for a-galactosidase, a-glucosidase, and 
|3-hexosaminidase activities (not shown) to ensure that 
overproduction of PPCA did not lead to aspecific release 
of other lysosomal proteins. Similar values for the three 
enzyme activities were measured in normal and trans­
genic samples, indicating that oversecretion of human 
PPCA was selective. Neuraminidase, being membrane 
bound, was not secreted and extracellular PPCA activity 
could not be tested because the precursor form of the 
protein is a zymogen, activated only in lysosomes. Con­
ditioned media and sera then were added separately to 
deficient galactosialidosis cells from an early infantile 
patient (Galjart et al. 1988). As shown in Table 3, cathep-
sin A, p-galactosidase, and neuraminidase activities 
were clearly enhanced upon uptake of the human PPCA 
precursor from either BM-conditioned medium or di­
rectly from transgenic mouse serum. No significant in­
crease in activity was detected in deficient fibroblasts 
treated with serum or BM-conditioned medium from 
normal mice. These results suggested that transgenic 
BM cells might achieve similar correction in vivo in af­
fected mice. 
Homozygous ( - / - ) mice, ranging in age from 2.5 to 5 
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Conditioned media (CM) from cultured BM cells and serum samples, both derived from either normal or transgenic (TG) mice, were 
added to PPCA ( - / - ) human galactosialidosis fibroblasts. After uptake, cell lysates were assayed for exogenous cathepsin A activitiy 
using the acylated dipeptide Z-Phe-Ala and for endogenous neuraminidase and p-galactosidase activities using synthetic 4-methyl-
umbelliferyl substrates. 
months, were lethally irradiated and transplanted, six 
with bone marrow from transgenic mice and six with 
bone marrow from normal mice. Both donor mouse lines 
were T cell depleted and were H-2B compatible with the 
affected recipients. The repopulated mice were moni­
tored for the level of storage material excreted in urine 
(Table 2). At 5 weeks after transplantation the total ex­
cretion of sialyloligosaccharides already was reduced to 
normal values, indicating that the PPCA provided by 
both transgenic and normal BM cells was sufficient to 
correct the accumulation of these storage products in 
urine. Furthermore, gross examination of transplanted 
animals, starting at 3 months post-BMT, showed com­
plete reversal of the diseased phenotype, as exemplified 
by the 10-month-old mouse shown in Fig. 2 (left), trans­
planted 5 months earlier with transgenic bone 
marrow. 
Histopathology of transplanted mice 
Tissue sections from kidney, liver, spleen, intestine, 
heart, lymph nodes, and brain of two ( - / - ) mice trans­
planted with bone marrow from either transgenic (BMT-
Tg) or normal donors (BMT-N) were compared with sim­
ilar sections from normal and untreated littermates 3 
months after transplantation. As shown in Fig. 5A, the 
abnormalities in the proximal tubular epithelium in the 
kidney of the BMT-N mouse were resolved practically, 
whereas storage vacuoles were still abundant in the glo­
merular epithelium. These aberrant features still per­
sisted in similarly treated mice examined 2 months 
later. In contrast, kidney specimens of the BMT-Tg 
mouse showed complete reversal of the diseased pheno­
type, even within the glomeruli, indicating that a higher 
dose of normal enzyme had a more beneficial and imme­
diate effect on this severely affected tissue. Clearance of 
storage material and normalization of cellular morphol­
ogy was apparent from the liver of mice treated either 
with normal or transgenic bone marrow (Fig. 5A). How­
ever, Kupffer cells with some vacuoles were encountered 
infrequently in liver sections of the BMT-N mouse, but 
not in corresponding sections of the BMT-Tg mouse. As 
expected, spleen (Fig. 5A) as well as bone marrow spec­
imens appeared completely normal. Most of the abnor­
malities in the colon, jejunum, and duodenum were cor­
rected, though the autonomic ganglia still showed a 
lesser degree of storage. In the heart vacuolated endothe­
lial cells and foamy histiocytes were no longer encoun­
tered. The lymph nodes of both types of transplanted 
mice had a normal appearance with no evidence of ac­
cumulation of foamy macrophages, although storage in 
occasional lymphoid cells was seen only in the speci­
mens from the BMT-N mice (not shown). In the brain of 
BM-transplanted mice storage neurons and perivascular 
as well as perineural vacuolated cells still could be iden­
tified (not shown). However, further quantitative assess­
ment is necessary to evaluate the effect of the BM trans­
plant in the brain. On the other hand, vacuolated cells in 
the choroid plexi (Fig. 5B), the trigeminal ganglia, and the 
pituitary had disappeared completely in both trans­
planted mice. 
In conclusion, reversal of the diseased phenotype 
clearly was significant in BMT-N mice but was more 
complete in BMT-Tg animals, supporting the idea that 
the release of a higher level of enzyme by overproducing 
donor BM cells is likely to be more effective for treat­
ment. 
Discussion 
Molecular and biochemical characteristics of PPCA 
(— / - ) mice correlate well with the most severe form of 
galactosialidosis in humans. Although viable and fertile, 
deficient mice present signs of illness very early in life 
with clear evidence of metabolic storage in cells from 
different organs. The edema, visceromegaly, and coarse 
face noticed in ( - / - ) animals are abnormalities charac­
teristic of the human disease phenotype. Nephropathy, 
which is a major complication and cause of death in 
early infantile patients (d'Azzo et al. 1995), is also the 
most apparent cause of physical deterioration in affected 
mice. Discrepancy in the severity of the disease between 
early infantile patients and young affected mice may be 
attributed simply to the much shorter gestation period of 
mice because the pathology of lysosomal disorders is 
largely associated with progressive accumulation of un-
degraded products in lysosomes, leading eventually to 
cellular dysfunction. The greater longevity of affected 
mice relative to human patients could also relate to the 
observed higher levels of p-galactosidase in some of the 
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Figure 5. Histology of BMT mice. (A) Sections from the kidney 
(Kid.), liver (Liv.), and spleen (Spl.) of a ( - / - ) mouse trans­
planted with either BMT-N or BMT-Tg were stained with to-
luidine blue (magnification, 400x). In the BMT-N kidney, stor­
age vacuoles still are apparent in the glomerular epithelium. In 
contrast, the BMT-Tg kidney shows complete correction of the 
lesions. In both BMT-N and BMT-Tg mice, the liver and the 
spleen show normal cellular morphology. However, in the 
BMT-N mouse, some of the Kupffer cells still are slightly vac­
uolated. [B] Haematoxylin/eosin-stained paraffin sections (mag­
nification, 400 x) of the choroid plexus from normal, affected, 
and transplanted mice. Storage in the epithelial cells of the ( - / 
- ) animal is signified by the dispersed staining of the cyto­
plasm. This aberration is reversed completely by transplanta­
tion with normal or transgenic BM. 
affected mouse tissues. Alternatively, but not exclusive 
of the first two, the difference may be caused by species-
specific variation in substrate metabolism. Similar ex­
planations may account for divergence in t ime of devel­
opment of the diseased phenotype for mice and humans 
with hexosaminidase A deficiency (Yamanaka et al. 
1994). Thus, in spite of the longer survival, galactosiali-
dosis mice are affected severely and can be considered a 
faithful model for the human disease. 
The deficiency of PPCA in tissues of mutant mice is 
accompanied by an equivalent loss of lysosomal neur­
aminidase activity, whereas p-galactosidase values are 
variable. Although in murine ( - / - ) fibroblasts the re­
sidual ^-galactosidase activity is consistent with that 
measured in patients' cells (d'Azzo et al. 1995), in other 
tissues the activity is either only slightly reduced or 
higher than normal levels. This finding may again reflect 
differences between species, although equivalent data for 
galactosialidosis patients are scarce, as autopsies are lim­
ited to a few cases from adult Japanese patients (Amano 
et al. 1983; Suzuki et al. 1984). The mouse results may 
be in line with earlier purification and coprecipitation 
studies, indicating that only a fraction of the p-galactosi-
dase and PPCA in mammalian tissues exists in the as­
sociated mode, whereas all neuraminidase activity is de­
tected in complex with the other two enzymes (Verhe-
ijen et al. 1985; Galjart et al. 1991; Hubbes et al. 1992). 
Thus, it is possible that in different murine cell types, 
p-galactosidase is stable whether or not associated with 
PPCA, whereas the interaction of neuraminidase with 
PPCA clearly is essential for its activity. The conse­
quences of the severe neuraminidase, rather than p-ga-
lactosidase, deficiency are reflected in the type of storage 
products present in urine of the ( - / - ) mice, which are 
mainly sialylated oligosaccharides, as observed in hu­
man patients (Amano et al. 1983; van Pelt et al. 1989). 
The pathological findings in the PPCA-deficient mice 
are consistent with those reported for galactosialidosis 
patients. Epithelial cells, endothelial cells, and macro­
phages are the first to show lesions in most organs, and 
the distribution of storage appears similar to that ob­
served in the Gaucher and Nieman Pick mouse models 
(Tybulewicz et al. 1992; Horinouchi et al. 1995; Otter-
bach and Stoffel 1995). The type and number of vacuo­
lated cells in galactosialidosis mice gradually increase 
with age. However, not all cells become affected and the 
extent of the damage is variable, even in older (— / —) 
animals. The profiles may depend on the metabolic state 
of the cells and the type of substrates to be catabolized, 
in particular by neuraminidase. Alternatively, it may re­
flect a microheterogeneity in the distribution of the nor­
mal protein in different cell types. We have shown pre­
viously that the protective and catalytic functions of 
PPCA are fully separable (Galjart et al. 1991), but the 
physiological significance of the cathepsin A activity is 
still unclear. We can speculate that in certain cells the 
protein exerts its activity outside the lysosomal com­
plex. In this case, loss of catalytic activity may not result 
in lysosomal storage. Perhaps evidence of a functional 
lesion will be found when knockout mice are screened 
for symptoms associated with loss of cathepsin A activ­
ity on peptides (e.g., substance P, oxytocin, or endothelin 
I), which may be substrates of the protein in vivo. 
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The most striking results of this study are those ob­
tained with BMT. The main aim for generating a mouse 
model for galactosialidosis was to evaluate therapeutic 
strategies that could be applicable to genetic correction 
of this and other similar disorders in humans. The pos­
sibility of manipulating autologous hematopoietic pro­
genitor cells in vitro that will express constitutively the 
correcting enzyme at high levels in the repopulated re­
cipient has important implications for somatic gene 
therapy of lysosomal disorders with CNS involvement. 
Transfer and expression of foreign genes into animal and 
human hematopoietic cells, as well as other cell types, 
has been achieved using different viral vectors (for re­
view, see Kay and Woo 1994). In designing a therapeutic 
approach for our galactosialidosis mouse model, we 
started with the supposition that the amount of normal 
enzyme (supplied by BM cells) would be crucial for ef­
fective correction. Thus, we have analyzed the conse­
quences of transplanting PPCA ( - / - ) mice with BM 
cells, derived from a transgenic line overexpressing the 
normal protein in a specific hematopoietic lineage. By 
analogy with other heterologous genes (van Assendelft et 
al. 1989; Needham et al. 1992), the LCR and p-globin 
cassette (used in this study) promote high expression of 
PPCA in erythroid precursor cells in a copy number-de­
pendent, position-independent fashion. Overexpression 
of the transgene results in the extracellular release of 
PPCA precursor that is readily taken up by deficient hu­
man cells via a mannose-6-phosphate-mediated endocy-
tosis. Hyper secretion is selective for the product of the 
transgene, as observed previously for other lysosomal en­
zymes overexpressed in various cell types (loannou et al. 
1992; Grubb et al. 1993; Kakkis et al. 1994). BMT has 
proven to be very effective for improvement of the dis­
eased phenotype. Treated PPCA ( - / - ) animals look 
completely normal and outlive the affected mice. Anal­
ysis of their tissues demonstrates that transplantation of 
the overexpressing bone marrow clearly is more effective 
than normal bone marrow for clearing storage in cells of 
visceral organs that undergo complete reversal of the le­
sions. The most plausible explanation of these data is 
that erythroid precursor cells secrete sufficient amounts 
of a stable PPCA precursor into the plasma to permit its 
ready uptake by cells in distant organs. Correction in the 
CNS, which mostly excludes plasma proteins because of 
the blood-brain barrier, is less evident but still notice­
able, especially in the epithelial cells of the choroid 
plexi. This is likely attributable to internalization of the 
heterologous human protein from the plasma via the 
mannose-6-phosphate receptor (Nilsson et al. 1992) and/ 
or the murine protein from donor-derived monocytes 
and perivascular macrophages. Detailed evaluation of 
the degree of CNS correction awaits fine mapping of the 
affected cells in different regions of the brain, which is 
currently in progress, and the analysis of a larger number 
of treated mice. Our findings conform in part with the 
results obtained with BMT in cats with the lysosomal 
storage disorder a-mannosidosis (Walkley et al. 1994a), 
another disorder of glycoprotein metabolism. These in­
vestigators report a clear improvement of the CNS le­
sions, but its extent is unclear, as no detailed spatial 
mapping of the storage neurons was presented. To im­
prove the correction of the CNS, we currently are testing 
whether transgenic bone marrow with targeted expres­
sion of PPCA in the monocyte/macrophage lineage 
would be more effective. Transplantation of young ani­
mals with such transgenic bone marrow is expected to be 
more beneficial because donor-derived monocytes and 
macrophages can become part of the microglial popula­
tion (Perry et al. 1985; Hickey and Kimura 1988). 
Although galactosialidosis affects only a small propor­
tion of the population, it has devastating consequences 
in children, with the early infantile form of the disease 
resulting in early death, multiple organ dysfunction, and 
mental retardation. There are, however, a limited num­
ber of patients, some of them diagnosed recently, in 
which the disease does not impair the CNS. Our findings 
indicate that somatic gene therapy approaches using au­
tologous human BM cells, which continuously express 
the correcting enzyme at high levels, may be feasible in 
the future as a cure of galactosialidosis, especially in 
mildly affected children. Moreover, they set the stage for 
the use of this approach in other lysosomal storage 
diseases. 
Materials and methods 
Construction of the PPCA targeting vector 
A mouse genomic clone encompassing the entire coding region 
of the PPCA gene was isolated from an EMBL-3 X phage library 
constructed with DNA from the CCE ES cell line derived from 
mouse strain 129Sv. PPCA DNA sequences contained in a 14-
kb Sail fragment were identified by restriction mapping and 
partial sequencing of exons. From this clone a 10-kb EcoRl-Sall 
fragment was subcloned into pTZ18 and used to generate the 
targeting vector. The hygro cassette (van Deursen and Wieringa 
1992) was inserted into exon 2 of the PPCA gene, 6 nucleotides 
downstream of the ATG start codon (see Fig. 1). In the resulting 
targeting vector, the hygro gene was flanked 5' and 3' by 3 and 
7 kb of homologous sequences, respectively. A 2.0-kb Sail frag­
ment of the herpes simplex virus thymidine kinase (HSV-TK) 
cassette was positioned 3' of the construct, outside the region of 
homology. Both positive and negative selectable markers were 
inserted in the antisense orientation with respect to the tran­
scriptional orientation of the PPCA gene and were driven by the 
TK promoter and PyF441 polyoma enhancer. 
Gene targeting in ES cells 
The 129/Ola-derived ES cell line E14 (a gift of Anton Berns, The 
Netherlands Cancer Institute, Amsterdam) was maintained in 
60% Buffalo rat liver (BRL)-conditioned Dulbecco's modified 
Eagle medium (DMEM)/40% fresh DMEM, 15% fetal bovine 
serum (FBS), 0.1 mM 2-mercaptoethanol, 2 mM glutamine, and 
1000 U/ml of leukemia inhibiting factor (GIBCO). The cells 
were trypsinized, resuspended at a concentration of 10^/ml in 
PBS, and electroporated at room temperature with 25 |xg of Sail 
linearized vector DNA at 117 V and 1200 JJLF for 10 msec, using 
a Progenetor II gene pulser (Hoeffer). After electroporation, cells 
were kept on ice for 10 min and transferred onto 10-cm culture 
dishes coated with 0.1% gelatin in above medium. After recov­
ery for 24 hr, cells were put on selection medium containing 188 
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M-g/ml of hygromycin B (Calbiochem) and 0.2 (JLM FIAU (1-[2-
deoxy, 2-fluoro-p-D-arabinofuranosyl]-5 iodouracil, a kind gift of 
Bristol Myers) for 7-10 days. Resistant colonies were expanded 
in 24-well plates; half of the cells in each well was cryopre-
served, and the other half was expanded for genotype analysis. 
Positive clones were stored in liquid nitrogen and thawed at 
least 3 days before blastocyst injection. 
Generation of mutant mice 
Blastocysts were isolated at day 3.5 postcoitum by flushing the 
uterine horns of naturally mated C57BL/6 pregnant females 
with DMEM plus 10% FBS. Approximately 10-15 ES cells from 
each homologous recombinant clone carrying 40 chromosomes 
were microinjected into recipient blastocysts, and 9-14 em­
bryos were transferred into the uterine horns of (C57BL/ 
6xCBA/Ca) Fj pseudopregnant fosters (Bradley 1987). Chimeric 
males were mated with C57BL/6 or FVB/f females, and germ-
line transmission of the mutant allele was verified by Southern 
blot analysis of tail DNA from Fi offspring with either agouti or 
gray coat color. Fj offspring from interbred heterozygotes was 
genotyped by Southern blotting to identify homozygous null 
mutants. The phenotypic alterations in PPCA ( - / - ) mice, as 
presented in this paper, were uniform and showed complete 
penetrance, irrespective of their genetic background. 
Southern and Northern Blot Analyses 
Genomic DNA isolated from ES cells or mouse tails was di­
gested with Ndel, resolved on a 0.8% agarose gel, and trans­
ferred onto Hybond-N+ membranes (Amersham). The 5' junc­
tion was checked by hybridization with a 1-kb EcoRl-Ndel 
probe positioned immediately 5' of the targeting construct, and 
the 3' junction was checked with a 0.5-kb PCR probe positioned 
immediately 3' of the targeting construct. Absence of additional 
random integrations of the targeting construct was checked 
with a hygro probe. Clones that contained the expected 5-kb 
Ndel fragment, diagnostic for homologous recombination, were 
obtained at a frequency of 1 in 7. For genotype analysis of tail 
DNA, only the 5' probe was used. Total RNA was isolated from 
brain, kidney, and liver tissues of 4-to 6-week-old mice as de­
scribed (Auffray and Rougeon 1980). RNA (15-20 |xg) was sep­
arated on a 1% agarose gel containing 0.66 M formaldehyde. 
After electrophoresis, the RNA was blotted onto a Zeta-probe 
membrane (Bio-Rad) and hybridized with the mouse cDNA 
probe. 
Enzyme activity assays and urine 
oligosaccharide determinations 
For enzyme activity assays, primary cultures of skin fibroblasts 
and tissues from affected and normal mice were homogenized in 
double-distilled water. Cathepsin A activity was measured with 
the synthetic dipeptide substrate Z-Phe-Ala, according to the 
procedure described earlier (Galjart et al 1991). The activities of 
(3-galactosidase and neuraminidase were assayed with artificial 
4-methylumbelliferyl substrates (Galjaard 1980). Total protein 
concentration was determined using the method of Smith et al. 
(1985). Total sialic acid content in urine was measured in 10 |xl 
samples after hydrolysis in 0.1 N Fi2S04 by a modification of the 
method of Aminoff (1961), as described in Wenger and Williams 
(1991). N-acetylneuraminic acid was used as a standard. Creat­
inine was measured in a fraction of each sample by the central 
diagnostic laboratory of Thomas Jefferson University (Philadel­
phia, PA). 
Histopathological analyses 
Tissues isolated from affected and BM-treated mice as well as 
normal or heterozygous littermates were fixed with 2% glut-
araldehyde in 0.2 M phosphate buffer, postfixed with 1% os­
mium tetroxide in 0.2 M phosphate buffer, dehydrated in graded 
ethanol (70% through absolute), en bloc stained with 4% uranyl 
acetate in absolute ethanol, and embedded in Spurr resin (Ladd 
Research Industries, Inc., Burlington, VT). Semi thin sections 
were cut at 470 nm and stained with toluidine blue for light 
microscopy. Sections for electron microscopy were cut at 85 nm 
and stained with 2% uranyl acetate/lead citrate and screened 
with JEOL 1200 EX II (JEOL USA Inc., Peabody, MA). For prep­
aration of paraffin sections, dissected tissues were fixed over­
night in 10% formalin. After dehydration and paraffin embed­
ding, 6-[jLm sections were made, mounted on slides, and stained 
with haematoxylin/eosin. For the analysis of the brain, affected 
and BM-treated mice were perfused through the left cardiac ven­
tricle with 4% paraformaldehyde in PBS. The cerebrum was 
sectioned coronally at the level of the optic chiasm. The ante­
rior half of the cerebrum, cerebellum, and brainstem were pro­
cessed for paraffin embedding, sectioned 6 |xm thick, and 
stained solochrome/eosin and luxol fast blue (LFB)/ PAS. The 
posterior half was cryosectioned serially at 10 ixm thick and 
stained with PAS. The trigeminal ganglia and pituitary gland 
were postfixed with osmium and processed for epoxy-resin em­
bedding as described above. 
Uptake in galactosialidosis fibroblasts 
BM cells from three normal and three transgenic mice were 
harvested by flushing the femurs with DMEM and 15% FBS. 
Cells were washed once with the same medium and seeded at a 
concentration of 1.5x 10^/ml in three 30 mm dishes. Then they 
were cultured for an additional 5 days in the above medium 
supplemented with 10 U/ml of erythropoietin (Amgen, Inc). 
The conditioned medium from each culture then was pooled 
and added to confluent galactosialidosis fibroblasts from an 
early infantile patient, seeded 5 days in advance in six-well 
plates. In parallel, serum samples from the same mice were also 
pooled, concentrated, and added to the deficient cells. Uptake 
was carried out for 4 days. Treated fibroblasts then were har­
vested by trypsinization and homogenized for enzymatic assays 
as above. 
BM transplantation 
The recipient galactosialidosis mice at 2.5-5 months of age 
were lethally irradiated with 9.25 Gy from a cesium irradiator, 
24 hr before transplant. Normal BM was derived from two 
C57BL/6 Thy 1.1 mice. Transgenic BM was derived from two 
mice of a (C57Bl/6xCBA) Fj transgenic line in which the hu­
man protective protein precursor is overexpressed in the ery-
throid lineage under the control of the ^-globin promoter and 
LCR. BM cells were harvested by flushing the femurs with 
Hanks medium with 5% FBS. Prior to BMT, donor cells were 
incubated with HO-22-1 and AT 83 antibodies for 15 min to 
deplete the T-cell population. A cell suspension (0.5 ml) con­
taining 2x 10^ cells/ml was injected intravenously into the tail 
vein. Starting at 3 months post-transplantation, tissues from 
both normal and transgenic BM-treated mice were isolated and 
prepared for light microscopy, as described above. 
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